IE 11 is a very old Browser and it`s not supported on this site

3. Financial risk management

Currency risk

The Group holds assets denominated in currencies other than the Swiss franc, the functional currency. It is therefore exposed to currency risk, as the value of the securities denominated in other currencies will fluctuate due to changes in exchange rates. Depending on the market situation the Group could use foreign currency options and/or forward contracts to reduce the currency risk.

The following exchange rates have been used for the preparation of these condensed consolidated interim financial statements:

Currency

 

30.06.2021

 

31.12.2020

USD

 

0.92500

 

0.88520

ANG

 

0.51966

 

0.49730

EUR

 

1.09672

 

1.08134

GBP

 

1.27940

 

1.21000

Fair values

The following table presents the Group’s assets that are measured at fair value (in CHF 1 000):

30.06.2021

 

Level 1

 

Level 2

 

Level 3

 

Total

Assets

 

 

 

 

 

 

 

 

Securities

 

 

 

 

 

 

 

 

– Shares

 

4 347 013

 

 

 

4 347 013

– Derivative instruments

 

 

 

2 252

 

2 252

Total assets

 

4 347 013

 

 

2 252

 

4 349 265

 

 

 

 

 

 

 

 

 

31.12.2020

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Securities

 

 

 

 

 

 

 

 

– Shares

 

3 952 504

 

 

 

3 952 504

– Derivative instruments

 

 

 

2 155

 

2 155

Total assets

 

3 952 504

 

 

2 155

 

3 954 659

The table below summarizes the transactions in level 3 instruments (in CHF 1 000):

 

 

01.01.–30.06.2021

 

01.01.–30.06.2020

Opening balance

 

2 155

 

2 355

Purchases/Sales/Reclassification

 

 

Gains/(losses) included in net gain/loss from securities

 

97

 

(49)

Closing balance

 

2 252

 

2 306

Gains/(losses) on level 3 instruments included in net gain/loss from securities

 

97

 

(49)

The level 3 instrument was allocated as part of a corporate action in 2019. There were no transfers between level 1, 2 and 3 during the reporting period.

For assets and liabilities carried at amortised cost, their carrying values are a reasonable approximation of fair value.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience.Use of cookies & disclaimer